세계의 혈관내피성장인자(VEGF) 시장 : 제품 유형, 최종 사용자 및 지역별 - 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031년)

Vascular Endothelial Growth Factor Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

US $ 4,995 ￦ 6,876,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,043,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,695,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

혈관내피성장인자(VEGF) 시장은 의학 연구의 발전과 다양한 혈관 관련 질환 및 상태를 치료하기 위한 효과적인 치료법에 대한 필요성이 증가함에 따라 최근 몇 년동안 큰 견인차 역할을 하고 있습니다. 시장 역학에 대해 자세히 조사하고 시장 규모, 성장 촉진요인, 과제, 기회, 경쟁 환경에 대한 주요 고찰을 담고 있습니다. 분석 기간은 2024년부터 2031년까지이며, 이해관계자들에게 전략적 의사결정과 사업 성장에 도움이 되는 귀중한 정보를 제공합니다.

세계 VEGF 시장은 2024-2031년 CAGR 10.7%로 확대될 것으로 예상되며, 2024년 시장 규모는 2억 6,170만 달러로 추정되며 2031년에는 5억 3,311만 달러에 달할 것으로 예상됩니다.

주요 인사이트

• 시장 가치 추정치(2024년) : 2억 6,170만 달러
• 예상 시장 가치(2031년) : 5억 3,311만 달러
• 세계 시장 성장률(2024-2031년 CAGR) : 10.7%.

VEGF 시장 - 보고서 범위 :

이 조사 보고서는 VEGF 시장에 대한 종합적인 분석을 제공하고 성장을 가속하는 주요 요인을 강조하며, VEGF는 새로운 혈관을 형성하는 과정인 혈관신생에서 그 역할로 인해 항암 치료의 중요한 표적입니다. 항 VEGF 치료는 다양한 유형의 암과 노화 관련 황반변성(AMD), 당뇨망막병증 및 기타 망막 질환을 치료하는 데 사용되고 있습니다. 암과 노화 관련 질환의 발생률 증가와 의학 연구 및 치료법의 발전은 VEGF 표적 치료제에 대한 수요를 촉진하고 있습니다.

시장 성장 촉진요인 :

세계적으로 암 발병률 증가는 VEGF 시장의 주요 촉진요인입니다. 암세포의 성장과 전이에 새로운 혈관이 필요하기 때문에 항 VEGF 치료는 다양한 암 치료의 핵심이 되고 있습니다. 또한, AMD와 같은 노화 관련 질환의 발병률이 증가하고 있는 것도 시장 성장에 기여하고 있습니다. 약물 전달 시스템 및 개인 맞춤형 의료 접근법의 기술 발전은 보다 효과적이고 표적화된 치료법으로 이어져 시장 확대에 기여하고 있습니다. 치료법 개선과 VEGF 억제제의 새로운 응용 분야에 대한 수요가 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다.

시장 성장 억제요인 :

잠재력에도 불구하고 VEGF 시장은 몇 가지 문제에 직면해 있습니다. 항 VEGF 치료는 고가이기 때문에 특히 의료 시스템이 발달하지 않은 지역에서는 일부 환자의 접근성이 제한될 수 있습니다. 또한, VEGF 억제제의 부작용은 고혈압, 상처 치유 장애와 같은 부작용으로 인해 환자에게 위험을 초래할 수 있습니다. 규제 장벽과 긴 승인 절차도 시장 성장에 영향을 미칠 수 있습니다. 이러한 요인들은 대체 요법과의 경쟁과 결합하여 시장 확대를 억제할 수 있습니다.

시장 기회 :

VEGF 시장에는 성장과 혁신의 큰 기회가 있습니다. 항 VEGF 치료제의 바이오시밀러 및 제네릭 의약품의 개발은 더 저렴한 치료법의 길을 열어 더 많은 환자군에 대한 접근성을 확대하고, VEGF 억제제의 새로운 치료 용도에 대한 지속적인 연구는 시장 다각화 가능성을 제공합니다. 또한 제약회사와 연구기관의 공동연구는 획기적인 치료법을 창출하고 VEGF 시장의 저변을 확대할 수 있습니다. 첨단 치료법에 대한 수요가 증가하고 있는 신흥 시장에 대한 투자는 시장 확대의 또 다른 기회입니다.

본 보고서에서 다룬 주요 질문들

• 2024-2031년 VEGF 시장의 예상 CAGR은?
• VEGF 시장의 성장을 가속하는 주요 요인은?
• VEGF 시장에서 가장 큰 점유율을 차지하는 지역은?
• 세계 VEGF 시장의 주요 기업은?
• VEGF 시장의 주요 성장 기회는?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/ 분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 주요 내용

• 총이익 분석
• 규제 시나리오
• 밸류체인 분석
• VEGF 시장 매출 비교(2019년과 2023년)

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19현재 통계와 향후 영향 가능성
• 현재 GDP 예측이라고 예상되는 영향
• 2008년과 비교한 현재 경제 예측 경제 분석
• COVID-19로 영향 분석
  • VEGF 유형별
  • VGEF 용도별
  • VEGF 발현 숙주별
  • 최종사용자별
  • 지역별
• 2023년 시장 시나리오

제7장 세계의 혈관내피세포성장인자(VEGF) 시장 수요(금액 또는 규모) 분석

• 과거 시장 매출 분석(2019년-2023년)
• 현재·향후 시장 매출 예측(2024년-2031년)
  • 전년대비 성장 동향 분석
  • 절대적 이익 기회 분석

제8장 세계의 혈관내피세포성장인자(VEGF) 시장 분석 : VEGF 유형별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : VEGF 유형별(2019년-2023년)
• 현재·향후 시장 규모 분석·예측 : VEGF 유형별(2024년-2032년)
  • 인간 VEGF
  • 쥐 VEGF
  • 토끼 VEGF
  • 래트 VEGF
  • 기타
• VEGF 유형별 시장의 매력 분석

제9장 세계의 혈관내피세포성장인자(VEGF) 시장 분석 : VGEF 용도별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : VGEF 용도별(2019년-2023년)
• 현재·향후 시장 규모 분석·예측 : VGEF 용도별(2024년-2032년)
  • 세포배양
  • 세포 기반 치료
  • 의약품 개발
  • 유전자 치료
  • 희귀질환 치료
  • 병용요법
  • 창상 치유 연구
  • 혈액학 연구
  • 뼈 형성
  • 항혈관 신생 요법
• VGEF 용도별 시장의 매력 분석

제10장 세계의 혈관내피세포성장인자(VEGF) 시장 분석 : 발현 숙주별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 발현 숙주별(2019년-2023년)
• 현재·향후 시장 규모 분석·예측 : 발현 숙주별(2024년-2032년)
  • HEK293 세포
  • 대장균
  • 곤충 세포
  • CHO
  • NS0
  • 기타
• 발현 숙주별 시장의 매력 분석

제11장 세계의 혈관내피세포성장인자(VEGF) 시장 분석 : 최종사용자별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 최종사용자별(2019년-2023년)
• 현재·향후 시장 규모 분석·예측 : 최종사용자별(2024년-2032년)
  • 제약 기업 및 바이오테크놀러지 기업
  • 연구센터 및 학술기관
  • CMO/CDMO
  • 기타 최종사용자
• 최종사용자별 시장의 매력 분석

제12장 세계의 혈관내피세포성장인자(VEGF) 시장 분석 : 지역별

• 서론
• 과거 시장 규모 분석 : 지역별(2019년-2023년)
• 현재·향후 시장 규모 분석·예측 : 지역별(2024년-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 남아시아
  • 동아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제13장 북미의 혈관내피세포성장인자(VEGF) 시장 분석

제14장 라틴아메리카의 혈관내피세포성장인자(VEGF) 시장 분석

제15장 유럽의 혈관내피세포성장인자(VEGF) 시장 분석

제16장 남아시아의 혈관내피세포성장인자(VEGF) 시장 분석

제17장 동아시아의 혈관내피세포성장인자(VEGF) 시장 분석

제18장 오세아니아의 혈관내피세포성장인자(VEGF) 시장 분석

제19장 중동 및 아프리카(MEA)의 혈관내피세포성장인자(VEGF) 시장 분석

제20장 시장 구조 분석

• 기업 계층별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제21장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁 구도
  • Thermo Fisher Scientific
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne(R&D Systems, Inc.)
  • GenScript
  • Miltenyi Biotec.
  • Abcam PLC.
  • Sino Biological Inc.
  • Cell Signaling Technology, Inc.
  • ACROBiosystems
  • STEMCELL Technologies
  • Creative Bioarray
  • PeproTech
  • Applied Biological Materials(abm) Inc.
  • GenWay Biotech
  • Leadgene Biomedical, Inc.
  • Boster Bio
  • Prospec-Tany Technogene Ltd.
  • Proteintech Group, Inc

제22장 사용된 전제조건과 두자어

제23장 조사 방법

LSH

영문 목차

영문목차

The Vascular Endothelial Growth Factor (VEGF) market has gained significant traction in recent years, driven by advances in medical research and the growing need for effective therapies to treat a range of vascular-related diseases and conditions. This comprehensive report from Persistence Market Research delves into the dynamics of the VEGF market, providing key insights into market size, growth drivers, challenges, opportunities, and competitive landscape. The analysis covers the period from 2024 to 2031, offering stakeholders valuable information to guide their strategic decisions and business growth.

The global VEGF market is projected to expand at a CAGR of 10.7% from 2024 to 2031, with a market value estimated at USD 261.7 million in 2024 and expected to reach USD 533.1 million by 2031.

Key Insights:

• Market Value Estimate (2024): USD 261.7 Million
• Projected Market Value (2031): USD 533.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2031): 10.7%

VEGF Market - Report Scope:

The report provides a comprehensive analysis of the VEGF market, highlighting key factors driving growth. VEGF is a significant target for anti-cancer therapies due to its role in angiogenesis, the process of forming new blood vessels. Anti-VEGF therapies are used to treat various types of cancers, as well as other conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases. The growing incidence of cancer and age-related diseases, coupled with advancements in medical research and treatment methods, has fueled demand for VEGF-targeting therapies.

Market Growth Drivers:

The increasing prevalence of cancer worldwide is a major driver for the VEGF market. As cancer cells require new blood vessels to grow and spread, anti-VEGF therapies have become a cornerstone in the treatment of various cancers. Additionally, the rising incidence of age-related diseases, such as AMD, has further contributed to market growth. Technological advancements in drug delivery systems and personalized medicine approaches have led to more effective and targeted therapies, fostering market expansion. The demand for improved treatments and the development of new applications for VEGF inhibitors are key factors driving the market's growth.

Market Restraints:

Despite its potential, the VEGF market faces certain challenges. The high cost of anti-VEGF therapies can limit access for some patients, especially in regions with less developed healthcare systems. Additionally, side effects associated with VEGF inhibitors, such as hypertension and impaired wound healing, can pose risks to patients. Regulatory hurdles and the lengthy process of drug approval also impact market growth. These factors, combined with competition from alternative therapies, can restrain the market's expansion.

Market Opportunities:

The VEGF market presents significant opportunities for growth and innovation. The development of biosimilars and generic versions of anti-VEGF therapies offers a pathway to more affordable treatments, expanding access to a broader patient base. Ongoing research into new therapeutic applications for VEGF inhibitors provides potential for market diversification. Furthermore, collaborations between pharmaceutical companies and research institutions can lead to groundbreaking treatments and expand the VEGF market's reach. Investment in emerging markets, where demand for advanced therapies is growing, represents another opportunity for market expansion.

Key Questions Addressed in the Report:

• What is the expected CAGR for the VEGF market between 2024 and 2031?
• What are the major factors driving growth in the VEGF market?
• Which regions hold the largest share of the VEGF market?
• Who are the key players in the global VEGF market?
• What are the main opportunities for growth in the VEGF market?

Competitive Landscape and Business Strategies:

The VEGF market features a competitive landscape with leading players like Genentech, Regeneron Pharmaceuticals, and Amgen. These companies focus on innovation, research and development, and strategic collaborations to maintain their market position. Genentech's Avastin, a widely used anti-VEGF drug, is a prominent example of a successful product in this sector. Regeneron Pharmaceuticals has also gained a significant market share with its product Eylea, used in the treatment of AMD and other retinal diseases.

Key business strategies include the development of new drug formulations, expansion into new therapeutic areas, and partnerships with other pharmaceutical companies. Companies are also focusing on expanding their presence in emerging markets and exploring biosimilar opportunities to increase their market reach.

Key Companies Profiled:

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Bio-Techne [R&D Systems, Inc.]
• GenScript
• Miltenyi Biotec.
• Abcam PLC.
• Sino Biological Inc.
• Cell Signaling Technology, Inc.
• ACROBiosystems
• STEMCELL Technologies

VEGF Market Segmentation:

VEGF Market by VEGF Type:

• Human VEGF
• Mouse VEGF
• Rat VEGF
• Rabbit VEGF
• Others VEGF

VEGF Market by Expression Host:

• CHO
• E. Coli
• HEK
• NSO
• Insect Cells
• Others

VEGF Market by Application:

• Cell Culture
• Cell-based Therapy
• Drug Development
• Gene Therapy
• Rare Disease treatment
• Wound Healing Research
• Combination Therapies
• Hematology Research
• Osteogenesis
• Anti-Angiogenic Therapy

VEGF Market by End User:

• Pharmaceutical & Biotechnology Companies
• Academic Institutes
• CMOs & CDMOs
• Other End Users

Research Centers & Laboratories

Hospital-attached Laboratories (HALs)

VEGF Market by Region:

• North America VEGF Market
• Latin America VEGF Market
• Europe VEGF Market
• South Asia VEGF Market
• East Asia VEGF Market
• Oceania VEGF Market
• Middle East & Africa VEGF Market

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusion And Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Inclusions

• 4.1. Gross Margin Analysis
• 4.2. Regulatory Scenario
• 4.3. Value Chain Analysis
• 4.4. VEGF Market Value Comparison 2019 and 2023

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Spending Outlook
  • 5.1.3. Global Growth Factor Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Advancements in Protein Characterization Techniques
  • 5.2.2. Increase in R&D Funding and Grants
  • 5.2.3. High Prevalence of Chronic Diseases
  • 5.2.4. New Product Launch
  • 5.2.5. Rising Research Activities for Rare Disease Indications
  • 5.2.6. Emergence of Novel Patented Technologies
  • 5.2.7. Collaborations and Agreements between Manufacturers
  • 5.2.8. Regulatory Approvals
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. Current COVID-19 Statistics and Probable Future Impact
• 6.2. Current GDP Projection and Probable Impact
• 6.3. Current Economic Projection as compared to 2008 Economic analysis
• 6.4. COVID-19 and Impact Analysis
  • 6.4.1. By VEGF Types
  • 6.4.2. By VGEF Application
  • 6.4.3. By VEGF Expression Hosts
  • 6.4.4. By End User
  • 6.4.5. By Region
• 6.5. 2023 Market Scenario

7. Global Vascular Endothelial Growth Factor (VEGF) Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Types

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By VEGF Types, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VEGF Types, 2024-2031
  • 8.3.1. Human VEGF
  • 8.3.2. Mouse VEGF
  • 8.3.3. Rabbit VEGF
  • 8.3.4. RAT VEGF
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis By VEGF Types

9. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VGEF Application

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By VGEF Application, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Application, 2024-2031
  • 9.3.1. Cell Culture
  • 9.3.2. Cell-Based Therapy
  • 9.3.3. Drug Development
  • 9.3.4. Gene Therapy
  • 9.3.5. Rare Disease Treatment
  • 9.3.6. Combination Therapies
  • 9.3.7. Wound Healing Research
  • 9.3.8. Hematology Research
  • 9.3.9. Osteogenesis
  • 9.3.10. Anti-Angiogenic Therapy
• 9.4. Market Attractiveness Analysis By VGEF Application

10. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, By VEGF Expression Hosts

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By VGEF Expression Hosts, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By VGEF Expression Hosts, 2024-2031
  • 10.3.1. HEK293 cells
  • 10.3.2. E. coli
  • 10.3.3. Insect Cells
  • 10.3.4. CHO
  • 10.3.5. NS0
  • 10.3.6. Others
• 10.4. Market Attractiveness Analysis By VGEF Expression Hosts

11. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by End User

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2031
  • 11.3.1. Pharmaceutical and Biotechnology Companies
  • 11.3.2. Research Centers & Academic Institutes
  • 11.3.3. CMO and CDMO
  • 11.3.4. Other End Users
    • 11.3.4.1. Research laboratories
    • 11.3.4.2. Hospital-Attached laboratories (HALs)
• 11.4. Market Attractiveness Analysis By End User

12. Global Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2031
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa
• 12.4. Market Attractiveness Analysis By Region

13. North America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By VEGF Types
  • 13.3.3. By VGEF Application
  • 13.3.4. By VGEF Expression Hosts
  • 13.3.5. By End User
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By VEGF Types
  • 13.4.3. By VGEF Application
  • 13.4.4. By VGEF Expression Hosts
  • 13.4.5. By End User
• 13.5. Key Market Participants - Intensity Mapping
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Country Level Analysis & Forecast
  • 13.7.1. U.S. Vascular Endothelial Growth Factor (VEGF) Market
    • 13.7.1.1. Introduction
    • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.1.2.1. By VEGF Types
      • 13.7.1.2.2. By VGEF Application
      • 13.7.1.2.3. By VGEF Expression Hosts
      • 13.7.1.2.4. By End User
  • 13.7.2. Canada Vascular Endothelial Growth Factor (VEGF) Market
    • 13.7.2.1. Introduction
    • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.7.2.2.1. By VEGF Types
      • 13.7.2.2.2. By VGEF Application
      • 13.7.2.2.3. By VGEF Expression Hosts
      • 13.7.2.2.4. By End User

14. Latin America Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By VEGF Types
  • 14.3.3. By VGEF Application
  • 14.3.4. By VGEF Expression Hosts
  • 14.3.5. By End User
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By VEGF Types
  • 14.4.3. By VGEF Application
  • 14.4.4. By VGEF Expression Hosts
  • 14.4.5. By End User
• 14.5. Key Market Participants - Intensity Mapping
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Country Level Analysis & Forecast
  • 14.7.1. Brazil Vascular Endothelial Growth Factor (VEGF) Market
    • 14.7.1.1. Introduction
    • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.1.2.1. By VEGF Types
      • 14.7.1.2.2. By VGEF Application
      • 14.7.1.2.3. By VGEF Expression Hosts
      • 14.7.1.2.4. By End User
  • 14.7.2. Argentina Vascular Endothelial Growth Factor (VEGF) Market
    • 14.7.2.1. Introduction
    • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.2.2.1. By VEGF Types
      • 14.7.2.2.2. By VGEF Application
      • 14.7.2.2.3. By VGEF Expression Hosts
      • 14.7.2.2.4. By End User
  • 14.7.3. Mexico Vascular Endothelial Growth Factor (VEGF) Market
    • 14.7.3.1. Introduction
    • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.7.3.2.1. By VEGF Types
      • 14.7.3.2.2. By VGEF Application
      • 14.7.3.2.3. By VGEF Expression Hosts
      • 14.7.3.2.4. By End User

15. Europe Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Russia
    • 15.3.1.8. Nordic Countries
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By VEGF Types
  • 15.3.3. By VGEF Application
  • 15.3.4. By VGEF Expression Hosts
  • 15.3.5. By End User
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By VEGF Types
  • 15.4.3. By VGEF Application
  • 15.4.4. By VGEF Expression Hosts
  • 15.4.5. By End User
• 15.5. Key Market Participants - Intensity Mapping
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Country Level Analysis & Forecast
  • 15.7.1. Germany Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.1.1. Introduction
    • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.1.2.1. By VEGF Types
      • 15.7.1.2.2. By VGEF Application
      • 15.7.1.2.3. By VGEF Expression Hosts
      • 15.7.1.2.4. By End User
  • 15.7.2. France Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.2.1. Introduction
    • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.2.2.1. By VEGF Types
      • 15.7.2.2.2. By VGEF Application
      • 15.7.2.2.3. By VGEF Expression Hosts
      • 15.7.2.2.4. By End User
  • 15.7.3. Italy Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.3.1. Introduction
    • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.3.2.1. By VEGF Types
      • 15.7.3.2.2. By VGEF Application
      • 15.7.3.2.3. By VGEF Expression Hosts
      • 15.7.3.2.4. By End User
  • 15.7.4. Spain Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.4.1. Introduction
    • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.4.2.1. By VEGF Types
      • 15.7.4.2.2. By VGEF Application
      • 15.7.4.2.3. By VGEF Expression Hosts
      • 15.7.4.2.4. By End User
  • 15.7.5. U.K. Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.5.1. Introduction
    • 15.7.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.5.2.1. By VEGF Types
      • 15.7.5.2.2. By VGEF Application
      • 15.7.5.2.3. By VGEF Expression Hosts
      • 15.7.5.2.4. By End User
  • 15.7.6. Benelux Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.6.1. Introduction
    • 15.7.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.6.2.1. By VEGF Types
      • 15.7.6.2.2. By VGEF Application
      • 15.7.6.2.3. By VGEF Expression Hosts
      • 15.7.6.2.4. By End User
  • 15.7.7. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.7.1. Introduction
    • 15.7.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.7.2.1. By VEGF Types
      • 15.7.7.2.2. By VGEF Application
      • 15.7.7.2.3. By VGEF Expression Hosts
      • 15.7.7.2.4. By End User
  • 15.7.8. Russia Vascular Endothelial Growth Factor (VEGF) Market
    • 15.7.8.1. Introduction
    • 15.7.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.7.8.2.1. By VEGF Types
      • 15.7.8.2.2. By VGEF Application
      • 15.7.8.2.3. By VGEF Expression Hosts
      • 15.7.8.2.4. By End User

16. South Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Thailand
    • 16.3.1.3. Indonesia
    • 16.3.1.4. Malaysia
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By VEGF Types
  • 16.3.3. By VGEF Application
  • 16.3.4. By VGEF Expression Hosts
  • 16.3.5. By End User
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By VEGF Types
  • 16.4.3. By VGEF Application
  • 16.4.4. By VGEF Expression Hosts
  • 16.4.5. By End User
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Country Level Analysis & Forecast
  • 16.7.1. India Vascular Endothelial Growth Factor (VEGF) Market
    • 16.7.1.1. Introduction
    • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.1.2.1. By VEGF Types
      • 16.7.1.2.2. By VGEF Application
      • 16.7.1.2.3. By VGEF Expression Hosts
      • 16.7.1.2.4. By End User
  • 16.7.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Market
    • 16.7.2.1. Introduction
    • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.2.2.1. By VEGF Types
      • 16.7.2.2.2. By VGEF Application
      • 16.7.2.2.3. By VGEF Expression Hosts
      • 16.7.2.2.4. By End User
  • 16.7.3. Malaysia Vascular Endothelial Growth Factor (VEGF) Market
    • 16.7.3.1. Introduction
    • 16.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.3.2.1. By VEGF Types
      • 16.7.3.2.2. By VGEF Application
      • 16.7.3.2.3. By VGEF Expression Hosts
      • 16.7.3.2.4. By End User
  • 16.7.4. Thailand Vascular Endothelial Growth Factor (VEGF) Market
    • 16.7.4.1. Introduction
    • 16.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.7.4.2.1. By VEGF Types
      • 16.7.4.2.2. By VGEF Application
      • 16.7.4.2.3. By VGEF Expression Hosts
      • 16.7.4.2.4. By End User

17. East Asia Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By VEGF Types
  • 17.3.3. By VGEF Application
  • 17.3.4. By VGEF Expression Hosts
  • 17.3.5. By End User
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By VEGF Types
  • 17.4.3. By VGEF Application
  • 17.4.4. By VGEF Expression Hosts
  • 17.4.5. By End User
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Country Level Analysis & Forecast
  • 17.7.1. China Vascular Endothelial Growth Factor (VEGF) Market
    • 17.7.1.1. Introduction
    • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.1.2.1. By VEGF Types
      • 17.7.1.2.2. By VGEF Application
      • 17.7.1.2.3. By VGEF Expression Hosts
      • 17.7.1.2.4. By End User
  • 17.7.2. Japan Vascular Endothelial Growth Factor (VEGF) Market
    • 17.7.2.1. Introduction
    • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.2.2.1. By VEGF Types
      • 17.7.2.2.2. By VGEF Application
      • 17.7.2.2.3. By VGEF Expression Hosts
      • 17.7.2.2.4. By End User
  • 17.7.3. South Korea Vascular Endothelial Growth Factor (VEGF) Market
    • 17.7.3.1. Introduction
    • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.7.3.2.1. By VEGF Types
      • 17.7.3.2.2. By VGEF Application
      • 17.7.3.2.3. By VGEF Expression Hosts
      • 17.7.3.2.4. By End User

18. Oceania Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By VEGF Types
  • 18.3.3. By VGEF Application
  • 18.3.4. By VGEF Expression Hosts
  • 18.3.5. By End User
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By VEGF Types
  • 18.4.3. By VGEF Application
  • 18.4.4. By VGEF Expression Hosts
  • 18.4.5. By End User
• 18.5. Key Market Participants - Intensity Mapping
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Country Level Analysis & Forecast
  • 18.7.1. Australia Vascular Endothelial Growth Factor (VEGF) Market
    • 18.7.1.1. Introduction
    • 18.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.7.1.2.1. By VEGF Types
      • 18.7.1.2.2. By VGEF Application
      • 18.7.1.2.3. By VGEF Expression Hosts
      • 18.7.1.2.4. By End User
  • 18.7.2. New Zealand Vascular Endothelial Growth Factor (VEGF) Market
    • 18.7.2.1. Introduction
    • 18.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.7.2.2.1. By VEGF Types
      • 18.7.2.2.2. By VGEF Application
      • 18.7.2.2.3. By VGEF Expression Hosts
      • 18.7.2.2.4. By End User

19. Middle East and Africa (MEA) Vascular Endothelial Growth Factor (VEGF) Market Analysis 2019-2023 and Forecast 2024-2031

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Market Taxonomy, 2024-2031
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. North Africa
    • 19.3.1.4. South Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By VEGF Types
  • 19.3.3. By VGEF Application
  • 19.3.4. By VGEF Expression Hosts
  • 19.3.5. By End User
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By VEGF Types
  • 19.4.3. By VGEF Application
  • 19.4.4. By VGEF Expression Hosts
  • 19.4.5. By End User
• 19.5. Key Market Participants - Intensity Mapping
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Country Level Analysis & Forecast
  • 19.7.1. GCC Countries Vascular Endothelial Growth Factor (VEGF) Market
    • 19.7.1.1. Introduction
    • 19.7.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.7.1.2.1. By VEGF Types
      • 19.7.1.2.2. By VGEF Application
      • 19.7.1.2.3. By VGEF Expression Hosts
      • 19.7.1.2.4. By End User
  • 19.7.2. Turkey Vascular Endothelial Growth Factor (VEGF) Market
    • 19.7.2.1. Introduction
    • 19.7.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.7.2.2.1. By VEGF Types
      • 19.7.2.2.2. By VGEF Application
      • 19.7.2.2.3. By VGEF Expression Hosts
      • 19.7.2.2.4. By End User
  • 19.7.3. South Africa Vascular Endothelial Growth Factor (VEGF) Market
    • 19.7.3.1. Introduction
    • 19.7.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.7.3.2.1. By VEGF Types
      • 19.7.3.2.2. By VGEF Application
      • 19.7.3.2.3. By VGEF Expression Hosts
      • 19.7.3.2.4. By End User
  • 19.7.4. North Africa Vascular Endothelial Growth Factor (VEGF) Market
    • 19.7.4.1. Introduction
    • 19.7.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.7.4.2.1. By VEGF Types
      • 19.7.4.2.2. By VGEF Application
      • 19.7.4.2.3. By VGEF Expression Hosts
      • 19.7.4.2.4. By End User

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. By Regional footprint of Players
  • 20.3.2. Device foot print by Players
  • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Thermo Fisher Scientific
    • 21.3.1.1. Overview & Key financials
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Key Financials
    • 21.3.1.4. Sales Footprint
    • 21.3.1.5. SWOT Analysis
    • 21.3.1.6. Analysis Commentary
    • 21.3.1.7. Strategy Overview
  • 21.3.2. Merck KGaA
    • 21.3.2.1. Overview & Key financials
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Key Financials
    • 21.3.2.4. Sales Footprint
    • 21.3.2.5. SWOT Analysis
    • 21.3.2.6. Analysis Commentary
    • 21.3.2.7. Strategy Overview
  • 21.3.3. Bio-Rad Laboratories, Inc.
    • 21.3.3.1. Overview & Key financials
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Key Financials
    • 21.3.3.4. Sales Footprint
    • 21.3.3.5. SWOT Analysis
    • 21.3.3.6. Analysis Commentary
    • 21.3.3.7. Strategy Overview
  • 21.3.4. Bio-Techne [R&D Systems, Inc.]
    • 21.3.4.1. Overview & Key financials
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Key Financials
    • 21.3.4.4. Sales Footprint
    • 21.3.4.5. SWOT Analysis
    • 21.3.4.6. Analysis Commentary
    • 21.3.4.7. Strategy Overview
  • 21.3.5. GenScript
    • 21.3.5.1. Overview & Key financials
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Key Financials
    • 21.3.5.4. Sales Footprint
    • 21.3.5.5. SWOT Analysis
    • 21.3.5.6. Analysis Commentary
    • 21.3.5.7. Strategy Overview
  • 21.3.6. Miltenyi Biotec.
    • 21.3.6.1. Overview & Key financials
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Key Financials
    • 21.3.6.4. Sales Footprint
    • 21.3.6.5. SWOT Analysis
    • 21.3.6.6. Analysis Commentary
    • 21.3.6.7. Strategy Overview
  • 21.3.7. Abcam PLC.
    • 21.3.7.1. Overview & Key financials
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Key Financials
    • 21.3.7.4. Sales Footprint
    • 21.3.7.5. SWOT Analysis
    • 21.3.7.6. Analysis Commentary
    • 21.3.7.7. Strategy Overview
  • 21.3.8. Sino Biological Inc.
    • 21.3.8.1. Overview & Key financials
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Key Financials
    • 21.3.8.4. Sales Footprint
    • 21.3.8.5. SWOT Analysis
    • 21.3.8.6. Analysis Commentary
    • 21.3.8.7. Strategy Overview
  • 21.3.9. Cell Signaling Technology, Inc.
    • 21.3.9.1. Overview & Key financials
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Key Financials
    • 21.3.9.4. Sales Footprint
    • 21.3.9.5. SWOT Analysis
    • 21.3.9.6. Analysis Commentary
    • 21.3.9.7. Strategy Overview
  • 21.3.10. ACROBiosystems
    • 21.3.10.1. Overview & Key financials
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Key Financials
    • 21.3.10.4. Sales Footprint
    • 21.3.10.5. SWOT Analysis
    • 21.3.10.6. Analysis Commentary
    • 21.3.10.7. Strategy Overview
  • 21.3.11. STEMCELL Technologies
    • 21.3.11.1. Overview & Key financials
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Key Financials
    • 21.3.11.4. Sales Footprint
    • 21.3.11.5. SWOT Analysis
    • 21.3.11.6. Analysis Commentary
    • 21.3.11.7. Strategy Overview
  • 21.3.12. Creative Bioarray
    • 21.3.12.1. Overview & Key financials
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Key Financials
    • 21.3.12.4. Sales Footprint
    • 21.3.12.5. SWOT Analysis
    • 21.3.12.6. Analysis Commentary
    • 21.3.12.7. Strategy Overview
  • 21.3.13. PeproTech
    • 21.3.13.1. Overview & Key financials
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Key Financials
    • 21.3.13.4. Sales Footprint
    • 21.3.13.5. SWOT Analysis
    • 21.3.13.6. Analysis Commentary
    • 21.3.13.7. Strategy Overview
  • 21.3.14. Applied Biological Materials (abm) Inc.
    • 21.3.14.1. Overview & Key financials
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Key Financials
    • 21.3.14.4. Sales Footprint
    • 21.3.14.5. SWOT Analysis
    • 21.3.14.6. Analysis Commentary
    • 21.3.14.7. Strategy Overview
  • 21.3.15. GenWay Biotech
    • 21.3.15.1. Overview & Key financials
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Key Financials
    • 21.3.15.4. Sales Footprint
    • 21.3.15.5. SWOT Analysis
    • 21.3.15.6. Analysis Commentary
    • 21.3.15.7. Strategy Overview
  • 21.3.16. Leadgene Biomedical, Inc.
    • 21.3.16.1. Overview & Key financials
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Key Financials
    • 21.3.16.4. Sales Footprint
    • 21.3.16.5. SWOT Analysis
    • 21.3.16.6. Analysis Commentary
    • 21.3.16.7. Strategy Overview
  • 21.3.17. Boster Bio
    • 21.3.17.1. Overview & Key financials
    • 21.3.17.2. Product Portfolio
    • 21.3.17.3. Key Financials
    • 21.3.17.4. Sales Footprint
    • 21.3.17.5. SWOT Analysis
    • 21.3.17.6. Analysis Commentary
    • 21.3.17.7. Strategy Overview
  • 21.3.18. Prospec-Tany Technogene Ltd.
    • 21.3.18.1. Overview & Key financials
    • 21.3.18.2. Product Portfolio
    • 21.3.18.3. Key Financials
    • 21.3.18.4. Sales Footprint
    • 21.3.18.5. SWOT Analysis
    • 21.3.18.6. Analysis Commentary
    • 21.3.18.7. Strategy Overview
  • 21.3.19. Proteintech Group, Inc
    • 21.3.19.1. Overview & Key financials
    • 21.3.19.2. Product Portfolio
    • 21.3.19.3. Key Financials
    • 21.3.19.4. Sales Footprint
    • 21.3.19.5. SWOT Analysis
    • 21.3.19.6. Analysis Commentary
    • 21.3.19.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료